{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:08:34Z","timestamp":1792408114464,"version":"4.4.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1038\/s41585-021-00534-5","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T17:03:26Z","timestamp":1635527006000},"page":"5-6","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Outer membrane vesicle vaccines for Neisseria gonorrhoeae"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5188-7946","authenticated-orcid":false,"given":"Evgeny A.","family":"Semchenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7094-3528","authenticated-orcid":false,"given":"Kate L.","family":"Seib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"534_CR1","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1016\/j.vaccine.2020.02.073","volume":"38","author":"SL Gottlieb","year":"2020","unstructured":"Gottlieb, S. L. et al. Gonococcal vaccines: public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine 38, 4362\u20134373 (2020).","journal-title":"Vaccine"},{"key":"534_CR2","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3109\/1040841X.2015.1105782","volume":"42","author":"JL Edwards","year":"2016","unstructured":"Edwards, J. L., Jennings, M. P., Apicella, M. A. & Seib, K. L. Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development. Crit. Rev. Microbiol. 42, 928\u2013941 (2016).","journal-title":"Crit. Rev. Microbiol."},{"key":"534_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","volume":"5","author":"M Unemo","year":"2019","unstructured":"Unemo, M. et al. Gonorrhoea. Nat. Rev. Dis. Primers 5, 79 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"534_CR4","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3201\/eid2206.151093","volume":"22","author":"J Whelan","year":"2016","unstructured":"Whelan, J., Kl\u00f8vstad, H., Haugen, I. L., Holle, M. R. & Storsaeter, J. Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection, Norway. Emerg. Infect. Dis. 22, 1137\u20131139 (2016).","journal-title":"Emerg. Infect. Dis."},{"key":"534_CR5","doi-asserted-by":"publisher","first-page":"S734","DOI":"10.1093\/ofid\/ofx180.002","volume":"4","author":"J Longtin","year":"2017","unstructured":"Longtin, J. et al. Possible impact of wide-scale vaccination against serogroup B Neisseria meningitidis on gonorrhea incidence rates in one region of Quebec, Canada. Open Forum Infect. Dis. 4, S734\u2013S735 (2017).","journal-title":"Open Forum Infect. Dis."},{"key":"534_CR6","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","volume":"390","author":"H Petousis-Harris","year":"2017","unstructured":"Petousis-Harris, H. et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet 390, 1603\u20131610 (2017).","journal-title":"Lancet"},{"key":"534_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.7774\/cevr.2019.8.2.110","volume":"8","author":"RFO Azze","year":"2019","unstructured":"Azze, R. F. O. A meningococcal B vaccine induces cross-protection against gonorrhea. Clin. Exp. Vaccine Res. 8, 110\u2013115 (2019).","journal-title":"Clin. Exp. Vaccine Res."},{"key":"534_CR8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","volume":"69","author":"EA Semchenko","year":"2018","unstructured":"Semchenko, E. A., Tan, A., Borrow, R. & Seib, K. L. The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae. Clin. Infect. Dis. 69, 1101\u20131111 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"534_CR9","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/infdis\/jiy609","volume":"219","author":"PT Beernink","year":"2018","unstructured":"Beernink, P. T. et al. A meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and overexpressed factor H binding protein elicits gonococcal bactericidal antibodies. J. Infect. Dis. 219, 1130\u20131137 (2018).","journal-title":"J. Infect. Dis."},{"key":"534_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab450","author":"KA Matthias","year":"2021","unstructured":"Matthias, K. A. et al. Meningococcal detoxified outer membrane vesicle vaccines enhance gonococcal clearance in a murine infection model. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiab450 (2021).","journal-title":"J. Infect. Dis."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00534-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00534-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00534-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T22:35:26Z","timestamp":1733956526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00534-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1038\/s41585-021-00534-5","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"assertion":[{"value":"29 October 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.A.S. and K.L.S. hold patents relating to gonococcal vaccine antigens.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}